Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 68

1.

Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.

Jafarabadi M, Ghanbari Z, Hashemi S, Nemati M, Haghollahi F, Azimi Nekoo E.

Acta Med Iran. 2015;53(2):125-8.

2.

Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.

Jafarabadi M, Jafarabadi L, Shariat M, Rabie Salehi G, Haghollahi F, Rashidi BH.

J Obstet Gynaecol Res. 2015 Jan;41(1):120-6. doi: 10.1111/jog.12483. Epub 2014 Nov 5.

PMID:
25369726
3.

[Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].

Kosilov KV, Loparev SA, Krasnykh MA, Kosilova LV.

Adv Gerontol. 2014;27(1):149-55. Russian.

PMID:
25051773
4.

Oxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian women.

Aziminekoo E, Ghanbari Z, Hashemi S, Nemati M, Haghollahi F, Shokuhi N.

J Family Reprod Health. 2014 Jun;8(2):73-6.

5.

[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].

Rechberger T, Kulik-Rechberger B, Miotła P, Wróbel A.

Ginekol Pol. 2014 Mar;85(3):214-9. Review. Polish.

PMID:
24783434
6.

Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women.

Ayeleke RO, Hay-Smith EJ, Omar MI.

Cochrane Database Syst Rev. 2013 Nov 20;11:CD010551. doi: 10.1002/14651858.CD010551.pub2. Review.

PMID:
24259154
7.

A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.

Gittelman M, Weiss H, Seidman L.

J Urol. 2014 Apr;191(4):1014-21. doi: 10.1016/j.juro.2013.11.019. Epub 2013 Nov 11.

PMID:
24231837
8.

Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial.

Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C.

J Am Med Dir Assoc. 2011 Nov;12(9):639-47. doi: 10.1016/j.jamda.2010.05.003. Epub 2010 Oct 2.

PMID:
21450183
9.

Validity and reliability of patient selected goals as an outcome measure in overactive bladder.

Cartwright R, Srikrishna S, Cardozo L, Robinson D.

Int Urogynecol J. 2011 Jul;22(7):841-7. doi: 10.1007/s00192-011-1360-0. Epub 2011 Jan 29.

PMID:
21279328
10.

Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.

Cartwright R, Srikrishna S, Cardozo L, Robinson D.

BJU Int. 2011 May;107(10):1612-7. doi: 10.1111/j.1464-410X.2010.09684.x. Epub 2010 Nov 11.

PMID:
21070569
11.

Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women.

Burgio KL, Goode PS, Richter HE, Markland AD, Johnson TM 2nd, Redden DT.

J Urol. 2010 Aug;184(2):598-603. doi: 10.1016/j.juro.2010.03.141. Epub 2010 Jun 19.

PMID:
20639023
12.

Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.

Cartwright R, Srikrishna S, Cardozo L, Robinson D.

BJU Int. 2011 Jan;107(1):70-6. doi: 10.1111/j.1464-410X.2010.09508.x.

PMID:
20626389
13.

In women with urinary incontinence how necessary is cystometry?

Saleem A.

J Pak Med Assoc. 2010 May;60(5):356-9.

PMID:
20527606
14.

Treatment of overactive bladder in women.

Hartmann KE, McPheeters ML, Biller DH, Ward RM, McKoy JN, Jerome RN, Micucci SR, Meints L, Fisher JA, Scott TA, Slaughter JC, Blume JD.

Evid Rep Technol Assess (Full Rep). 2009 Aug;(187):1-120, v. Review.

15.

Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review.

Arruda RM, Castro R, Sartori M, Girão MJ.

Curr Opin Obstet Gynecol. 2009 Oct;21(5):412-4. doi: 10.1097/GCO.0b013e32832fd28f. Review.

PMID:
19593131
16.

Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment.

Wang AC, Chen MC, Kuo WY, Lin YH, Wang YC, Lo TS.

Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jul;20(7):819-25. doi: 10.1007/s00192-009-0860-7. Epub 2009 Apr 10.

PMID:
19495544
17.

Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.

Wong C, Duggan P.

J Obstet Gynaecol. 2009 Jan;29(1):31-4. doi: 10.1080/01443610802628726.

PMID:
19280492
18.

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.

Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G.

J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.

PMID:
19233423
19.

[Economic impact of overactive bladder symptoms in Japan].

Inoue S, Kobayashi M, Sugaya K.

Nihon Hinyokika Gakkai Zasshi. 2008 Nov;99(7):713-22. Japanese.

20.

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.

Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, Koochaki P.

Int J Clin Pract. 2008 Nov;62(11):1664-74. doi: 10.1111/j.1742-1241.2008.01893.x. Epub 2008 Sep 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk